Jason H. Karnes, PharmD, PhD, BCPS, FAHA

Associate Professor, Pharmacy Practice and Science
Assistant Professor, Sarver Heart Center, University of Arizona College of Medicine
Assistant Professor, Division of Pharmacogenomics, Center for Applied Genetics and Genomic Medicine (TCAG2M)
Alternate Member, Institutional Review Board (IRB), University of Arizona Human Subjects Protection Program
Director of Scientific Programs, AllofUs Research Program, University of Arizona - Banner Health
Adjunct Assistant Professor, Department of Biomedical Informatics, Vanderbilt University School of Medicine
Track Director, PharmD/PhD Dual Degree Program

Dr. Karnes' primary area of research interest is cardiovascular pharmacogenomics, specifically investigating the utility of genetic polymorphisms to predict toxicities of cardiovascular drugs. He employs a translational approach to investigate pharmacogenomic associations using observational studies, functional genomics techniques, and eventually prospective clinical trials. His ultimate career goal is to facilitate personalized cardiovascular medicine and genotype-guided prescribing to avoid serious cardiovascular drug toxicities.

Dr. Karnes is an author on 47 peer-reviewed manuscripts and 36 abstracts presented at national and international meetings.  He is active in multiple professional societies including the American Society for Clinical Pharmacology and Therapeutics, the American Heart Association, and the American College of Clinical Pharmacy. He has received funding for his research from the National Institutes of Health, the American Heart Association, the Flinn Foundation, and the American College of Clinical Pharmacy.

View UA Profile

Education & Post Graduate Training: 

Research Fellowship, Division of Clinical Pharmacology, Vanderbilt University School of Medicine (Tennessee), 2015
PhD, Clinical Pharmaceutical Sciences, University of Florida College of Pharmacy, 2012
PharmD (Cum Laude), University of Florida College of Pharmacy, 2008
BA, Ancient Greek, College of William and Mary (Virginia), 2004

Areas of Research: 

Clinical and Translational Research
Genotype-Guided Prescribing
Adverse Drug Reactions
Cardiovascular Pharmacogenomics
Personalized Medicine

Select Publications


Karnes JH, Rettie AE, Somogyi AA, et al. "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and HLA-B Genotypes and Phenytoin Dosing: 2020 Update." Clin. Pharmacol. Ther.. 2020. PMID: 32779747


Karnes JH, Wiener HW, Schwantes-An T-H, et al. "Genetic Admixture and Survival in Diverse Populations with Pulmonary Arterial Hypertension." Am. J. Respir. Crit. Care Med.. 2019;201(11):1407-1415. PMCID: PMC7258627  PMID: 31916850
Patanwala AE, Norwood C, Steiner H, et al. "Psychological and Genetic Predictors of Pain Tolerance." Clin Transl Sci. 2019;12(2):189-195. PMCID: PMC6440569  PMID: 30468309
Karnes JH, Miller MA, White KD, et al. "Applications of Immunopharmacogenomics: Predicting, Preventing, and Understanding Immune-Mediated Adverse Drug Reactions." Annu. Rev. Pharmacol. Toxicol.. 2019;59:463-486. PMCID: PMC6409210  PMID: 30134124


Karnes JH. "Pharmacogenetics to prevent heparin-induced thrombocytopenia: what do we know?" Pharmacogenomics. 2018;19(18):1413-1422. PMID: 30398086


Karnes JH, Shaffer CM, Cronin R, et al. "Influence of Human Leukocyte Antigen (HLA) Alleles and Killer Cell Immunoglobulin-Like Receptors (KIR) Types on Heparin-Induced Thrombocytopenia (HIT)." Pharmacotherapy. 2017;37(9):1164-1171. PMCID: PMC5600645  PMID: 28688202
Karnes JH, Bastarache L, Shaffer CM, et al. "Phenome-wide scanning identifies multiple diseases and disease severity phenotypes associated with HLA variants." Sci Transl Med. 2017;9(389). PMCID: PMC5563969  PMID: 28490672